NEWS

WIRES

OTHER

Triessent(R) Becomes HCSC's Specialty Pharmacy Provider

The Triessent program helps clients address rising specialty costs by providing an approach to specialty pharmacy management that integrates across pharmacy and medical benefits. The Triessent program focuses on three core services as a foundation for complete specialty management: safe and efficient delivery of specialty medications; education and guidance from experienced professionals for managing specialty conditions and the benefits that apply to them; and an integrated approach that streamlines medical and pharmacy benefit management.

"Our relationship with our Blue Cross and Blue Shield clients ensures alignment of interests. Through Triessent, Prime can help our clients improve financial controls in this growing area without compromising a commitment to quality member care," says Tim Dickman, President and Chief Executive Officer, Prime.

"HCSC is excited to be able to partner with Prime in developing a comprehensive specialty program that is fully integrated with our medical management activities," said Kevin Slavik, Senior Pharmacy Director of HCSC. "With the implementation of Triessent, our members will experience the high-touch, personalized and coordinated care management they need to manage their health conditions."

Health Care Service Corporation is a Mutual Legal Reserve Company, an independent licensee of the Blue Cross and Blue Shield Association.

Prime Therapeutics is a pharmacy benefit management company dedicated to providing, innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 14.6 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered inSt. Paul, Minnesota, Prime Therapeutics is collectively owned by 11 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at http://www.primetherapeutics.com.

SOURCE Prime Therapeutics